Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

Inclusion Criteria: * Age 18-65. * Diagnosed breast cancer，received chemotherapy. * ECOG performance status 0 or 1. * ANC≥1.5×10 9/L, PLT≥100×10 9/L. No bone marrow metastasis,blood coagulation function normally, no Hemorrhagic tendency. * Leukocyte reduction occurred after chemotherapy,WBC≤3.0x109/L or ANC≤1.5x109/L. * No obvious abnormal ecg examination. * Cr，TBIL, AST, ALT≤1.5×ULN，no serious underlying disease. * Signed informed consent. Exclusion Criteria: * Chemotherapy within past 4 weeks. * Uncontrolled inflammatory disease,axillary temperature≥38℃. * Merging other malignant tumor. * Pregnancy or nursing status. * Participation in another clinical trial with and investigational product within 3 months prior to study entry. * Severe diabetes mellitus, or poor blood sugar controller. * Allergic disease or allergic constitution. History of protein allergy. * History of drug addiction and alcoholism. * Hematopoietic stem cell transplantation or organ transplantation. * Received antibiotic treatment within 72 hours before chemotherapy. * Long-term use of hormones or immunosuppressive agents. * Severe mental or neurological disorders. * Chronic disease of severe cardiac, kidney and liver. * Other conditions that would be excluded from this study according to doctors'judgment.